Biotech Values

[DewDiligence]

MNTA Insider Shareholdings

[Updated for SEC filings through 8/5/10.]


FDA approval of generic Lovenox on 7/23/10 triggered the vesting of
restricted shares held by MNTA’s executive officers, which incurred
an income-tax liability for these officers. On MNTA’s 2Q10 CC on
8/3/10, CFO Rick Shea disclosed that some officers planned to sell
shares to cover their tax liability from the newly vested shares. On
8/5/10, Form-4’s were filed by Wheeler, Venkataraman, and Brugger.

The table entries below include both ordinary and restricted shares
and both vested and non-vested options.

 
                             Shares    Options 
 Officers 
 *Craig Wheeler (CEO)       428,641    675,000 
 *G Venkataraman‡ (SVP/R&D) 364,290    189,325 
 *Steven Brugger (COO)      209,779    246,194 
 *John Bishop (SVP/Pharma)   49,549    121,860 
 *Richard Shea (CFO)         40,471    249,200 
 *Bruce Leicher (Gen Cnsl)   38,734    137,050 
 *James Roach (CMO)          18,032    205,250 
  
 Directors 
 John Clarke                 77,123    126,000 
 †Bruce Downey                    0     45,000 
 Marsha Fanucci                   0    126,000 
 Peter Hutt                  67,863    201,500 
 *‡Ram Sasisekharan         306,344    126,000 
 *Bennett Shapiro             7,000    140,450 
 Elizabeth Stoner                 0     79,200 
 James Sulat (Chairman)           0     60,000 
 ======================   =========  ========= 
 All fifteen insiders     1,607,826  2,728,029 
  
 *10b5-1 selling plan in effect. 
 †Joined BoD 6/11/09. 
 ‡Co-founder.